Evaluation of Cathepsin D immunostaining in colorectal adenocarcinoma

Journal of Surgical Oncology

Volumn 65, Issue 4, 1997, Pages 242-248

  Theodoropoulos, George E ^a,b   Panoussopoulos, Dimitris ^a   Lazaris, Andreas Ch ^a   Golematis, Basil Ch ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE   (United States)

Author keywords

Adenocarcinoma; Cathepsin D; Colorectal cancer; Dukes' stage; Immunohistochemistry; Prognosis; Protease; Treatment

Indexed keywords

CATHEPSIN D;

ADENOCARCINOMA; ARTICLE; CARCINOMA CELL; COLORECTAL CARCINOMA; DISEASE COURSE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PHENOTYPE; PRIORITY JOURNAL;

EID: 0030872639     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199708)65:4<242::AID-JSO4>3.0.CO;2-5     Document Type: Article

References (54)

1. Schwartz MK: Tissue cathepsins as tumor markers. Clin Chim Acta 1995;237:67-78.
2. Webb EC: Enzyme nomenclature 1992: Recommendation of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology, San Diego, Academic Press, 1992, p374-421.
3. Agarwal S: Protease cathepsins - A view. Biochem Educ 1990; 18:67-72.
4. Greenbaum LM: Cathepsins and known forming and destroying enzymes. In Boyer PK (ed): 3rd ed. New York: Academic Press, 1971, p479-483.
5. Barrett AJ: "Cathepsin D and Other Carboxylproteinases." Amsterdam, Elsevier/North Holland, 1977, p209-229.
6. Leto G, Gebbia N, Rausa L, Trumminello FM: Cathepsin D in the malignant progression of neoplastic diseases. Anticancer Res 1992; 12:235-240.
7. Westley B, Rochefort H: A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell 1980;20:353-362.
8. Westley B, Rochefort H: Estradiol induced proteins in the MCF-7 human breast cancer cell line. Biochem Biophys Res Commun 1979;90:410-416.
9. Vignon F, Capony F, Chambon M, et al.: Autocrine growth stimulation of the MCF-7 breast cancer cells by the estrogen-regulated 52 K protein. Endocrinology 1986;118:1537-1545.
10. Westley B, May FE, Brown AM, et al.: Effects of antiestrogens on the estrogen-regulated p52 RNA and the 52- and 160-kilodalton proteins in MCF7 cells and two tamoxifen-resistant sublines. J Biol Chem 1984;259:10030-10035.
11. Morisset M, Capony F, Rochefort H: The 52-kDa estrogen-induced protein secreted by MCF7 cells is a lysosomal acidic protease. Biochem Biophys Res Commun 1986;138:102-109.
12. Capony F, Morrisset M, Barrett AJ, et al.: Phosphorylation, glycosylation and proteolytic activity of the 52 Kd estrogen-induced protein secreted by MCF7 cells. J Cell Biol 1987;104:253-262.
13. Yonezawa S, Takahashi T, Wang XJ, et al.: Structures at the proteolytic processing region of cathepsin D. J Biol Chem 1988; 263:16504-16511.
14. Capony F, Rougeot C, Montcourrier P, et al.: Increased secretion, altered processing, and glycosylation of pro-cathepsin D in human mammary cells. Cancer Res 1989;49:3904-3909.
15. Reid WA, Valler MJ, Kay J: Immunolocalization of cathepsin D in normal and neoplastic human tissues. J Clin Pathol 1986;39: 1323-1330.
16. Saku T, Sakai H, Tsuda N, et al.: Cathepsins D and E in normal metaplastic, dysplastic, and carcinomatous gastric tissue: an immunohistochemical study. Gut 1990;31:1250-1255.
17. Pujol P, Maudelonde T, Daures JP, et al.: A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer 1993;71:2006-2012.
18. Briozzo P, Morisset M, Capony F, et al.: In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells. Cancer Res 1988;48:3688-3692.
19. Maudelonde T, Khalaf S, Garcia M, et al.: Immunoenzymatic assay of Mr 52,000 cathepsin D in 182 breast cancer cytosols: Low correlation with other prognostic markers. Cancer Res 1988; 48:462-466.
20. Thorpe SM, Rochefort H, Garcia M, et al.: Association between high concentrations of Mu 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 1989;49:6008-6014.
21. Tandon AK, Clark GM, Chamness GC, et al.: Cathepsin D and prognosis in breast cancer. N Engl J Med 1990;322:297-302.
22. Spyratos F, Maudelonde T, Bronillet JP, et al.: Cathepsin D: An independent prognostic factor for the metastasis of breast cancer. Lancet: 1989;1115-1118.
23. Duffy MJ, Bronillet JP, Reilly D, et al.: Cathepsin D concentration in breast cancer cytosols: Correlation with biochemical, histological and clinical findings. Clin Chem 1991;37:101-104.
24. Granata G, Coradini D, Capelletti V, Di Fronzo G: Prognostic relevance of cathepsin D versus estrogen receptors in node-negative breast cancers. Eur J Cancer 1991;27:970-972.
25. Graf M, Baici A, Strauli P: Histochemical localization of cathepsin B at the invasion front of the rabbit V2 carcinoma. Lab Invest 1981;45:587-596.
26. Johnson MD, Torri JA, Lippman ME, Dickson RB: The role of cathepsin D in the invasiveness of human breast cancer cells. Cancer Res 1993;53:873-877.
27. Tetu B, Brisson J, Cote C, et al.: Prognostic significance of cathepsin D expression in node-positive breast carcinoma: an immunohistochemical study. Int J Cancer 1993;55:429-435.
28. Berus EM, Kliju JG, Schmitt M, et al.: Occurrence and interrelationships of urokinase-type plasminogen activator inhibitor-1 and cathepsin D in human ovarian tissues. Proc Am Ass Cancer Res 1994;35:69.
29. Metaye T, Millet C, Kraimps J, et al.: Estrogen receptors and cathepsin D in human thyroid tissue. Cancer 1993;72:1991-1996.
30. Watanabe M, Higashi M, Hashimoto M: Elevation of tissue cathepsin B and L activities in gastric cancer. Hepatogastroenterol 1987;34:120-122.
31. Watanabe M, Higashi J, Watanabe A, et al.: Cathepsin B and L activities in gastric cancer tissue: Correlation with histological findings. Biochem Med Metabol Biol 1989;42:21-29.
32. Allgayer H, Heiss MM, Babic R, et al: Expression of tumor-associated proteases and their inhibitors in gastric cancer: Impact on prognosis. Proc Amer Ass Canc Res 1995;3G:93.
33. Theodoropoulos GE, Lazaris AC, Panoussopoulos D, et al.: Significance of estrogen receptors and cathepsin D tissue detection in gastric adenocarcinoma. J Surg Oncol 1995;58:176-183.
34. Matsuo K, Kobayashi I, Tsukuba T, et al.: Immunohistochemical localization of cathepsins D and E in human gastric cancer. Hum Pathol 1996;27:997-998.
35. Dauson PM, Shausha S, Blai SD: Oestrogen receptors in colorectal cancer. J Clin Pathol 1990;43:149-151.
36. Piantelli M, Ricci R, Larocca LM, et al.: Type II oestrogen binding sites in human colorectal carcinoma. J Clin Pathol 1990;43: 1004-1006.
37. Galandiuk S, Mireljic S, Yang AR, et al.: Expression of hormone receptors, cathepsin D, and HER-2/neu oncoprotein in normal colon and colonic disease. Arch Surg 1993;128:637-642.
38. Leto G, Russo A, Tumminello FM, et al.: Cathepsin B and D activity levels in colorectal cancer: correlation with other prognostic parameters of malignant progression. Proc Am Assoc Canc Res 1994;35:69.
39. Tumminello FM, Gebbia N, Pizzolanti G, et al.: Correlation with cathepsin D activity and other biologic parameters: A preliminary report. Oncol 1995;52:237-242.
40. Valentini AM, Pirelli H, Armentano R, Caruso ML: The immunohistochemical expression of cathepsin D in colorectal cancer. Anticancer Res 1996;16:77-80.
41. Henry JA, McCarthy AL, Angus B, et al.: Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer: An immunohistochemical study. Cancer 1990;65:265-271.
42. Valentini AM, Amati L, Pirrelli M, et al.: Immunohistochemical expression of pS2 and cathepsin D in breast cancer: Relationship with ER, PgR immunostaining and clinicopathological aspects. Oncol Rep 1994;1:858-590.
43. Leto G, Tumminello FM, Russo A, et al.: Cathepsin D activity levels in colorectal cancer: Correlation with cathepsin B and L and other biological and clinical parameters. Int J Oncol 1994;5:509-515.
44. Rochefort H, Capony F, Garcia M: Cathepsin D: A protease involved in breast cancer metastasis. Cancer Metastasis Rev 1990; 9:321-331.
45. Cavailes V, Garcia M, Rochefort H: Regulation of cathepsin D and pS2 gene expression by growth factors in MCF7 human breast cancer cells. Mol Endocrinol 1989;3:552-558.
46. Mathieu M, Rochefort H, Barenton B, et al.: Interactions of cathepsin D and insulin-like growth factor-II (IGF-II) on the IGF-II mannose-6-phosphate receptor in human breast cancer cells and possible consequences on milogenic activity of IGF-II. Mol Endocrinol 1990;4:1327-1335.
47. Brouillet JP, Theillet C, Maudelonde T, et al.: Cathepsin D assay in primary breast cancer and lymph nodes: Relationship with c-myc, c-erbB-2 and int-2 oncogene amplification and node invasiveness. Eur J Cancer 1990;26:437-441.
48. Faust PL, Kornfeld S, Chirgwin JM: Cloning and sequence analysis of cDNA for human cathepsin D. Proc Natl Acad Sci USA 1985;82:4910-4914.
49. Augereau P, Garcia M, Mattei MG, et al.: Cloning and sequencing of the 52 K cathepsin D complementary deoxyribonucleic acid of MCF7 breast cancer cells and mapping on chromosome 11. Mol endocrinol 1988;2:186-192.
50. Johnson MD, Torri JA, Lippman ME, Dickson RB: The role of cathepsin D in the invasiveness of human breast cancer cells. Cancer Res 1993;53:873-877.
51. Rogers S, Day CA, Fox SB: Expression of cathepsin D and estrogen receptor in male breast carcinoma. Hum Pathol 1993;24: 148-151.
52. 0 breast carcinoma. Am J Surg Pathol 1994;18:158-166.
53. Charpin C, Devictor B, Bergeret D, et al.: CD 31 quantitative immonocytochemical assays in breast carcinomas. Correlation with current prognostic factors. Am J Clin Path 1995;103:443-448.
54. Safe SH: Modulation of gene expression and endocrine response pathways by 2,3,7,8-tetrachlorodibenzo-p-dioxin related compounds. Pharmac Ther 1995;64:2476-281.